Last reviewed · How we verify
Nebivolol I
At a glance
| Generic name | Nebivolol I |
|---|---|
| Also known as | Metoprolol I |
| Sponsor | Trinity Hypertension & Metabolic Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (PHASE4)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
- Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine (PHASE4)
- The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension (PHASE2)
- Comparative Study of the Effects of Telmisartan and Nebivolol (PHASE4)
- The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol I CI brief — competitive landscape report
- Nebivolol I updates RSS · CI watch RSS
- Trinity Hypertension & Metabolic Research Institute portfolio CI